Tesamorelin

Tesamorelin (TH9507) Growth Hormone Releasing Hormone Analog | Research Use Only

What it is

Tesamorelin is a synthetic 44 amino acid polypeptide analog of growth hormone releasing hormone, often abbreviated GHRH. It is designed to bind GHRH receptors in the pituitary and stimulate endogenous growth hormone release, which can increase circulating insulin like growth factor 1, also called IGF 1. (ncbi.nlm.nih.gov)

Origins and development

Tesamorelin is the active ingredient in the prescription product Egrifta and Egrifta SV. The FDA labeling states it is indicated for reduction of excess abdominal fat in HIV infected adult patients with lipodystrophy, and the labeling also notes key limitations, including that long term cardiovascular safety has not been established and it is not indicated for weight loss management. Initial U.S. approval is listed as 2010 in the Egrifta SV prescribing information. (accessdata.fda.gov)

Molecular profile

PubChem lists tesamorelin with molecular formula C221H366N72O67S and molecular weight about 5136 g per mol. (pubchem.ncbi.nlm.nih.gov)
Mechanistically oriented references describe it as a 44 amino acid peptide with modifications intended to improve stability and pharmacokinetics compared with native GHRH. (ncbi.nlm.nih.gov)

Scientific overview

Tesamorelin is studied as a GHRH receptor agonist that promotes growth hormone release from the pituitary. This upstream stimulation is distinct from administering growth hormone directly, because it is designed to engage the body’s endogenous growth hormone axis, with downstream IGF 1 production described in mechanistic summaries. Translation of pathway effects depends on population, protocol, and clinical context. (ncbi.nlm.nih.gov)

Clinical research

Tesamorelin has an FDA approved clinical use in a specific population, reduction of excess abdominal fat in HIV infected adults with lipodystrophy, as described in the official prescribing information. The label also includes multiple warnings, contraindications, and monitoring considerations that define its clinical risk profile and limitations of use. (accessdata.fda.gov)

What researchers study with tesamorelin

Key research focus areas often include
• Endocrine signaling along the GHRH, growth hormone, IGF 1 axis
• Pharmacokinetics and stability of modified GHRH analogs
• Body composition endpoints in HIV associated lipodystrophy populations, as reflected in the approved indication and supporting studies in labeling (accessdata.fda.gov)

Regulatory and compliance notice

Research Use Only. Not for human or veterinary use. Tesamorelin is a prescription drug ingredient in FDA approved products for a specific indication and must not be marketed as a dietary supplement or promoted for unapproved uses. Refer to FDA prescribing information for approved clinical labeling and limitations of use. (accessdata.fda.gov)

Citations and references

1. FDA prescribing information for Egrifta SV tesamorelin for injection, includes indication, limitations, and initial U.S. approval 2010.
   (accessdata.fda.gov)

2. NCBI Bookshelf LiverTox tesamorelin monograph, includes description as a 44 amino acid GHRH analog and mechanism leading to growth hormone and IGF 1.
   (ncbi.nlm.nih.gov)

3. PubChem tesamorelin compound record, includes molecular formula and molecular weight.
   (pubchem.ncbi.nlm.nih.gov)

If you want this to match your ProsperX Labs template perfectly, tell me whether you want the header to read Tesamorelin acetate or just Tesamorelin, since some suppliers label the salt form differently.